| Anomalie ou Maladie associée : | | |
| Les patients souffrant de SPM présentent une diminution des bêta-endorphines la semaine précédant les règles et pendant les premiers jours de l'écoulement menstruel Syndrome prémenstruel .. cacher .... voir plus .. aussi appelés troubles dysphoriques prémenstruels, dans sa forme sévère ... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Référence : | | |
| Neuropeptide levels in
premenstrual syndrome .. cacher .... voir plus .. ... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Periovulatory beta-endorphin levels in
premenstrual syndrome .. cacher .... voir plus .. ... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Facchinetti F, Martignoni E, Petraglia F, Sances MG, Nappi G, Genazzani AR.
Premenstrual fall of plasma beta-endorphin in patients with premenstrual
syndrome. Fertil Steril. 1987 Apr;47(4):570-3. .. cacher .... voir plus .. Plasma beta-endorphin (beta-EP), beta-lipotropin (beta-LPH), and cortisol
concentrations were measured by perimenstrual period in 11 patients affected by
premenstrual syndrome (PMS) and in 8 asymptomatic healthy volunteers. Blood
samples were collected every 2 to 3 days, for 1 month, starting from midcycle.
The Menstrual Distress Questionnaire (MDQ) was administered during the testing
period. Plasma beta-LPH and cortisol levels remain stable during the
perimenstrual period, in both controls and PMS patients. On the contrary, PMS
patients showed a decrease of plasma beta-EP in the week preceding menses and
during the first days of menstrual flow. Beta-EP values of PMS patients regain
normal levels during the next follicular phase. No changes of beta-EP levels were
recorded in asymptomatic women. MDQ scores revealed that PMS patients complained
of water retention, pain discomfort, and mood swings. The transient and
reversible decrease of plasma beta-EP in PMS patients near to and at menses
remains to be clarified. ... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Evidence for the involvement of β-endorphin in the human menstrual cycle .. cacher .... voir plus .. The possibility that β-endorphin, an endogenous opiate, is involved in the regulation of the menstrual cycle was examined. Daily serum β-endorphin levels, in conjunction with luteinizing hormone, progesterone, and 17β-estradiol were measured during 26 hormonally normal menstrual cycles. Twenty-one cycles showed a preovulatory peak and postovulatory trough of β-endorphin, 2 cycles had a postovulatory peak, and 3 had a postovulatory peak with sustained elevation. The raw data were standardized by conversion to “Z-scores,” and the composite values were computed for each of the three classes described above. Significance within these three classes was assessed using a one-way analysis of variance with an F-ratio at 95% confidence limits. The composite plot of the 26 cycles showed a statistically significant preovulatory peak occurring 2 days prior to the luteinizing hormone surge and a postovulatory trough of β-endorphin 5 days later. These results suggest that β-endorphins play a significant role in the neurochemical mechanisms of gonadotropin release. ... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS.
Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric
disorder. Health Psychol. 2002 Jul;21(4):358-67 .. cacher .... voir plus .. This study examined pain sensitivity and pain modularity mechanisms (e.g., beta-endorphin levels, blood pressure) in women with premenstrual dysphoric disorder (PMDD; n = 27) and healthy controls (n = 27) during the follicular and luteal phases of the menstrual cycle. Physiological measures were taken during rest and ischemic pain testing. In both cycle phases, PMDD women (a) displayed lower resting cortisol and beta-endorphin levels and (b) exhibited shorter pain threshold and tolerance times and greater pain unpleasantness ratings during pain. PMDD women also reported greater pain unpleasantness and intensity and had lower beta-endorphin levels in their luteal phase and tended to display higher blood pressure levels at rest and during pain testing. Results suggest that endogenous opioids may be pathophysiologically relevant to PMDD and that the hypothalamic-pituitary-gonadal axis may modulate pain sensitivity in PMDD ... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Giannini AJ, Melemis SM, Martin DM, Folts DJ. Symptoms of premenstrual
syndrome as a function of beta-endorphin: two subtypes. Prog Neuropsychopharmacol
Biol Psychiatry. 1994 Mar;18(2):321-7 .. cacher .... voir plus .. 1. Forty six women presenting with symptoms of premenstrual syndrome (PMS) were studied. Ages ranged from 21 to 32. All women answered a questionnaire based on DSM-III-R criteria. They then had serum beta-endorphin levels drawn on day 1 and day 20 of their menstrual Cycle. 2. Beta-endorphin levels were compared with symptom presentation. Such symptoms as anxiety, food cravings and physical discomfort were associated with significant decline in beta-endorphin. Other symptoms were found equally distributed in both groups. The existence or absence of beta-endorphin decline in specific PMS subgroup was postulated. ... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Eifer DB, Collins RL. Current concepts of beta-endorphin physiology in female
reproductive dysfunction. Fertil Steril. 1990 Nov;54(5):757-71. Review .. cacher .... voir plus .. beta-Endorphin has a role in the regulation of the normal menstrual cycle and possibly in the onset of puberty. We have reviewed the evidence pointing to an alteration in this neuropeptide that may contribute to the pathogenesis of various reproductive dysfunctions. Elevated or high levels of beta-endorphin have been associated with exercise-associated amenorrhea, stress-associated amenorrhea, and polycystic ovarian syndrome. Depressed or low levels of beta-endorphin have been associated with PMS and menopause. Alterations in the levels of beta-endorphin may change the pulsatile release of GnRH via noradrenergic and/or dopaminergic pathways. We have primarily focused on beta-endorphin as representative of the endogenous opioid peptides, but other opioid peptides may also contribute to the pathogenesis of various types of reproductive dysfunction. Perhaps it will become possible to characterize and hone our understanding of the function of beta-endorphin and the other substances composing the endogenous opioid peptides. A better understanding of their role in physiological as well as pathophysiological processes may allow for the development of rational approaches to the treatment of specific disorders pertaining to reproduction. Many questions remain unanswered. Among the most relevant are: what is the precise mechanism of action by which beta-endorphin exerts its influence on pulsatile GnRH release? Is there a functional relationship between CNS and peripheral (serum) levels of beta-endorphin? Are the detected changes in beta-endorphin levels merely associated, or are they a cause of a particular disorder? Since it took almost 40 years between the time prostaglandins were first discovered and eventual realization of their clinical application, it may take some time before the beta-endorphin story is complete. ... lire plus sur ce sujet dans un nouvel onglet.... | | |